Government Owned Inventions Available for License: Fluorophthalimides as Anti-Inflammatory Agents for Systemic and Neurodegenerative Disorders
The National Institute on Aging (NIA) seeks research co- development partners and/or licensees for the pre-clinical and clinical development of the compounds as anti-inflammator...
The National Institute on Aging (NIA) seeks research co-development partners and/or licensees for the pre-clinical and clinical development of the compounds as anti-inflammatory therapeutics for systemic and neurodegenerative disorders.
FOR FURTHER INFORMATION CONTACT:
Inquiries related to this license opportunity should be directed to: Nikki Guyton, Ph.D., Unit Supervisor, NCI, Technology Transfer Center, Email:
( printed page 35992)
guytonn@nih.gov
or Phone: 240-276-5493.
SUPPLEMENTARY INFORMATION:
Numerous systemic, as well as neurological disorders, have a hallmark inflammatory element that can drive disease progression. However, the use of currently available anti-inflammatory agents have failed to demonstrate efficacy as potential treatment for systemic and neurological disorders in clinical trials.
The immunomodulatory imide drug (IMiD) thalidomide exerts anti-inflammatory effects through inhibition of tumor necrosis factor-alpha (TNF-α), which is a master regulator of the inflammatory response. Researchers at the National Institute on Aging (NIA) have synthesized novel thalidomide analogs possessing potent anti-inflammatory actions but, importantly, hinder the cerebon binding that associated with the adverse teratogenic actions of classic IMiDs. This invention has potential to be developed as therapeutics for a variety of systemic and neurological disorders including inflammatory disorders, autoim.
“This Notice is in accordance with 37 CFR 404.4 Authority to grant licenses.”
NIH Reference Number:
E-151-2022.
Related Technologies:
E-045-2012-0; E-208-2015-0.
Product Type:
Therapeutic.
Therapeutic Area(s):
Oncology | Neurology.
Development Stage:
Pre-clinical (
in vivo
validation).
Patent Information:
US Nonprovisional Patent Application, US 19/102,830, filed on February 2, 2025. Status: Pending.
Publication:
Lecca D, et al. Novel, thalidomide-like, non-cereblon binding drug etrafluorobornylphthalimide mitigates inflammation and brain injury. (PMID 36872339).
Potential Commercial Applications:
Neurodegenerative diseases.
Inflammatory disorders.
Autoimmune disorders.
Viral infections.
Cancer.
Competitive Advantages:
More potent anti-inflammatory properties.
Potentially clinically safer than classic IMiDs by lower risk of fetal malformations.
Potential to treat a wide range of significant unmet medical needs.
Dated: June 10, 2026.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer Institute.
Use this for formal legal and research references to the published document.
91 FR 35991
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Government Owned Inventions Available for License: Fluorophthalimides as Anti-Inflammatory Agents for Systemic and Neurodegenerative Disorders,” thefederalregister.org (June 15, 2026), https://thefederalregister.org/documents/2026-11926/government-owned-inventions-available-for-license-fluorophthalimides-as-anti-inflammatory-agents-for-systemic-and-neurod.